Lara is SVP, Head of Research and Translational Science at Resolution Therapeutics, a spin-out of the University of Edinburgh. Her long-term research interest is the role of regenerative macrophages in tissue repair, and how to translate their therapeutic potential to treat chronic inflammatory diseases with a fibrotic component. In her role at Resolution, she sets the Research strategy and oversees its execution to promote the progression of the lead asset RTX001 through the preclinical and clinical stages.

I currently serve as the Vice President, Translational Science and Scientific Affairs at Altimmune, Inc. I am an immunologist by training.

Dr. Xuehai Liang is Co-founder and CEO of Arnatar Therapeutics, Inc. He has more than 25 years of experience in RNA biology, antisense technology, and RNA-targeted drug discovery and development. Prior to founding Arnatar, Dr. Liang spent more than 12 years at Ionis Pharmaceuticals, where he served as Executive Director and led Core Antisense Research, advancing antisense mechanisms, oligonucleotide chemistry, and therapeutic discovery.

This session addresses disparities and structural barriers in liver disease care, along with predictive/ML-based tools and novel care delivery models (telehealth, quality measures) to improve outcomes.

This session showcases emerging prediction and diagnostic tools across hepatology, including AI-assisted guideline synthesis, novel fibrosis risk scores, and exercise-based interventions in cirrhosis.

This session focuses on chronic hepatitis D (delta), covering emerging therapies (bulevirtide, lonafarnib, novel entry inhibitors) and international epidemiologic data.

This session reviews progress toward functional cure in chronic hepatitis B, featuring phase 2/3 data on bepirovirsen, siRNA therapy, and immune correlates of HBsAg decline.

This session examines mechanisms of treatment resistance in hepatobiliary cancers, including tumor microenvironment and immune evasion pathways driving resistance to immunotherapy.

This session covers drug-induced liver injury across multiple contexts — statins, checkpoint inhibitors, acetaminophen, and GLP-1 agonists — using registry data, organoid models, and AI-based case triage tools.

This session examines factors modifying disease course in PSC and autoimmune hepatitis, including alcohol exposure, statin use, pruritus therapies, and post-transplant recurrence risk.